132 related articles for article (PubMed ID: 37946299)
21. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.
Bellone S; McNamara B; Mutlu L; Demirkiran C; Hartwich TMP; Harold J; Yang-Hartwich Y; Siegel ER; Santin AD
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240216
[TBL] [Abstract][Full Text] [Related]
22. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.
Ma C; Yang X; Xing W; Yu H; Si T; Guo Z
Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608
[TBL] [Abstract][Full Text] [Related]
23. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
24. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
Shi Y; Su H; Song Y; Jiang W; Sun X; Qian W; Zhang W; Gao Y; Jin Z; Zhou J; Jin C; Zou L; Qiu L; Li W; Yang J; Hou M; Xiong Y; Zhou H; Du X; Wang X; Peng B
EBioMedicine; 2020 Apr; 54():102731. PubMed ID: 32304999
[TBL] [Abstract][Full Text] [Related]
25. Assessment of ctDNA in CSF may be a more rapid means of assessing surgical outcomes than plasma ctDNA in glioblastoma.
Li JH; He ZQ; Lin FH; Chen ZH; Yang SY; Duan H; Jiang XB; Al-Nahari F; Zhang XH; Wang JH; Zhang GH; Zhang ZF; Li C; Mou YG
Mol Cell Probes; 2019 Aug; 46():101411. PubMed ID: 31173881
[TBL] [Abstract][Full Text] [Related]
26. Central Nervous System Lymphoma.
Shah T; Venur VA
Semin Neurol; 2023 Dec; 43(6):825-832. PubMed ID: 37995744
[TBL] [Abstract][Full Text] [Related]
27. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
[No Abstract] [Full Text] [Related]
28. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
[TBL] [Abstract][Full Text] [Related]
29. Postoperative circulating tumor DNA can refine risk stratification in resectable lung cancer: results from a multicenter study.
Fu R; Huang J; Tian X; Liang C; Xiong Y; Zhang JT; Jiang B; Dong S; Gong Y; Gao W; Li F; Shi Y; Liu Z; Gao X; Chen R; Zhong W; Zhang Y
Mol Oncol; 2023 May; 17(5):825-838. PubMed ID: 36732646
[TBL] [Abstract][Full Text] [Related]
30. Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas.
Kim SJ; Kim YJ; Yoon SE; Ryu KJ; Park B; Park D; Cho D; Kim HY; Cho J; Ko YH; Park WY; Kim WS
Cancer Res Treat; 2023 Jan; 55(1):291-303. PubMed ID: 35240014
[TBL] [Abstract][Full Text] [Related]
31. APRIL and BAFF: novel biomarkers for central nervous system lymphoma.
Mulazzani M; Huber M; Borchard S; Langer S; Angele B; Schuh E; Meinl E; Dreyling M; Birnbaum T; Straube A; Koedel U; von Baumgarten L
J Hematol Oncol; 2019 Oct; 12(1):102. PubMed ID: 31615554
[TBL] [Abstract][Full Text] [Related]
32. Circulating Tumor DNA in Lymphoma.
Kambhampati S; Zain J
Curr Hematol Malig Rep; 2022 Dec; 17(6):298-305. PubMed ID: 36214943
[TBL] [Abstract][Full Text] [Related]
33. Circulating tumor DNA by high-throughput sequencing of T cell receptor monitored treatment response and predicted treatment failure in T cell lymphomas.
Zhang W; Wang W; Han X; Gan Y; Qian L; Zhang Y; Zhang C; Wang Y; Guan Y; Yang L; Zhou D
Int J Lab Hematol; 2021 Oct; 43(5):1041-1049. PubMed ID: 33734593
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
[TBL] [Abstract][Full Text] [Related]
35. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.
Scherer F; Kurtz DM; Newman AM; Stehr H; Craig AF; Esfahani MS; Lovejoy AF; Chabon JJ; Klass DM; Liu CL; Zhou L; Glover C; Visser BC; Poultsides GA; Advani RH; Maeda LS; Gupta NK; Levy R; Ohgami RS; Kunder CA; Diehn M; Alizadeh AA
Sci Transl Med; 2016 Nov; 8(364):364ra155. PubMed ID: 27831904
[TBL] [Abstract][Full Text] [Related]
36. Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study.
Wu JJ; Wang WH; Dong M; Ma SS; Zhang XD; Zhu LN; Niu ST; Ding MJ; Zhang JM; Zhang L; Li X; Li L; Sun ZC; Wang XH; Fu XR; Li ZM; Chang Y; Nan FF; Yan JQ; Yu H; Wu XL; Zhou ZY; Zhang MZ
Invest New Drugs; 2022 Jun; 40(3):650-659. PubMed ID: 35137332
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the Oncomine Pan-Cancer Cell-Free Assay for Analyzing Circulating Tumor DNA in the Cerebrospinal Fluid in Patients with Central Nervous System Malignancies.
Shah M; Takayasu T; Zorofchian Moghadamtousi S; Arevalo O; Chen M; Lan C; Duose D; Hu P; Zhu JJ; Roy-Chowdhuri S; Riascos RF; Chen H; Luthra R; Esquenazi Y; Ballester LY
J Mol Diagn; 2021 Feb; 23(2):171-180. PubMed ID: 33531134
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies.
Tie J; Cohen JD; Lo SN; Wang Y; Li L; Christie M; Lee M; Wong R; Kosmider S; Skinner I; Wong HL; Lee B; Burge ME; Yip D; Karapetis CS; Price TJ; Tebbutt NC; Haydon AM; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Popoli M; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Int J Cancer; 2021 Feb; 148(4):1014-1026. PubMed ID: 32984952
[TBL] [Abstract][Full Text] [Related]
39. Cerebrospinal fluid circulating tumour DNA as a liquid biopsy for central nervous system malignancies.
Escudero L; Martínez-Ricarte F; Seoane J
Curr Opin Neurol; 2020 Dec; 33(6):736-741. PubMed ID: 33177377
[TBL] [Abstract][Full Text] [Related]
40. [Clinical Characteristics and Prognosis of 21 Cases of Acute Lymphoblastic Leukemia with Central Nervous System Leukemia].
Jin XS; Yang L; Wang BH; Li HH; Yu L; Jing Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1675-1682. PubMed ID: 28024476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]